Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial.

What the trial testedas reported · 4,401 people · 2022

Not counted

−46%−65% to −16%

Bigger than 9 in 10 for cardiovascular events

As reported

HR 0.54, 95% CI 0.35–0.84

the abstract, start to end

… death) in EA participants (hazard ratio 0.54, 95% confidence interval …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.540.35–0.84

SGLT2 inhibitorsCardiovascular events

1 / 3

2022

2023

2024

2025

2026

this paperpooled ittrialcites it